< Back to situations

Get alerts on this situation

We’ll email you as it develops, and you can follow the whole thread from day one.

Unsubscribe anytime.

[SITUATION] · [ACTIVE]

7 clusters · 70 sources · 29 days · First seen 29 days ago · Last updated about 11 hours ago

Categories: HEALTH · BUSINESS

US FDA panel advances peptide compounding approvals

Entities: Robert F. Kennedy Jr. · Semaglutide · BPC-157 · Ezekiel Emanuel · Marty Makary

Overview

Late June 2026 the FDA announced a two‑day advisory meeting to reassess injectable synthetic peptides. On 22 July the Pharmacy Compounding Advisory Committee met and, despite an internal scientific review urging caution, added BPC‑157, KPV, TB‑500 and MOTS‑C to the Category 1 bulk‑drug list. The next day the panel voted 8‑6 (one abstention) to recommend seven unapproved peptides for the Section 503A Bulk Drug Substances List. On 25 July the committee narrowly approved six of those seven for inclusion, endorsing BPC‑157 for ulcerative colitis, MOTS‑C for obesity and osteoporosis, and KPV and TB‑500 for wound healing; semax and epitalon also cleared, while emideltide failed by a single vote. Reported vote margins were 8‑6 for some compounds and 7‑5 for others. Members, largely appointed by Health Secretary Robert F. Kennedy Jr., included doctors and pharmacists with disclosed financial ties to the peptide industry. FDA staff reiterated that the scientific evidence does not meet safety and efficacy standards and warned of quality‑control, adverse‑event reporting, and precedent concerns. The recommendation is non‑binding; a final FDA decision will follow a public comment period amid rising pressure from wellness‑influencer and biohacking communities.

Claims

What the coverage asserts, and how well corroborated each claim is across sources.

[● 5 SOURCES] Six of seven peptide compounds were approved for addition to the 503A Bulks List.
[● 5 SOURCES] FDA staff warned that the scientific evidence does not support approval of the peptides for safety and efficacy.
[● 5 SOURCES] The panel’s recommendation is non‑binding; the FDA will issue a final decision after a public comment period.
[● 4 SOURCES] The FDA Pharmacy Compounding Advisory Committee voted to recommend adding BPC‑157 to the 503A Bulks List for compounding. (recommended for ulcerative colitis)
[● 4 SOURCES] The vote reflects growing pressure from wellness influencers and 'biohacking' communities to broaden access to unproven peptide substances.
[● 3 SOURCES] Emideltide was the only peptide rejected, losing by a single vote.
[● 3 SOURCES] Voting margins were narrow, reported as 8‑6 for some compounds and 7‑5 for others.
[● 2 SOURCES] The advisory panel included members with financial ties to the peptide industry, appointed by HHS Secretary Robert F. Kennedy Jr.

Timeline

about 11 hours ago

[HEALTH] 2 sources
FDA proposes restrictions on compounded weight‑loss and peptide drugs
The FDA proposes to bar compounding of key weight‑loss GLP‑1 drugs and faces criticism after an advisory panel endorsed six additional peptides, raising safety and conflict‑of‑interest concerns.
3 days ago

[HEALTH] 7 sources
FDA Advisory Panel Approves Six Peptides for Compounding Use
The FDA’s Pharmacy Compounding Advisory Committee voted to recommend six peptides—including BPC‑157 and MOTS‑c—for compounding, rejecting only emideltide. The narrow vote and industry‑linked panel raise safety‑
6 days ago

[HEALTH] 38 sources
FDA panel eases restrictions on popular peptides
The FDA’s advisory panel voted 8‑6 to recommend adding several unapproved peptides—BPC‑157, KPV, TB‑500 and others—to the compounding list, despite safety concerns and industry ties, potentially opening a $2‑3
7 days ago

[HEALTH] 2 sources
US FDA Approves Four Peptides for Compounding Amid Generic Drug Tariff Debate
Trump proposes 100% tariffs on US generics, while the FDA’s PCAC adds four peptide drugs to the 503A compounding list, marking a shift in drug policy.
8 days ago

[HEALTH] 15 sources
FDA panel to review popular peptides as wellness demand surges
The FDA’s advisory panel is reviewing seven popular peptides for possible compounding pharmacy use amid growing wellness demand and industry pressure, but scientific reviewers cite limited safety data.
22 days ago

[BUSINESS] 2 sources
FDA to classify peptide drugs, boosting Novo Nordisk, pressuring Hims & Hers
The FDA plans to classify peptide drugs, lifting Novo Nordisk's shares, pressuring Hims & Hers, and sparking caution over unregulated peptide supplements.
29 days ago

[HEALTH] 9 sources
FDA to review controversial peptide drugs with industry‑linked panel
The FDA will meet next month to review seven controversial peptide injections, using a panel that now includes doctors, pharmacists and a Tennessee senator with industry ties, despite agency scientists warning‑

Sources

abc17news.com · arstechnica.com · artsquest.org · autismadventures.com · bbgstrategy.com · bio.news · bmwdallasrepair.com · brand-studio.fortune.com · ca.sports.yahoo.com · canadianaffairs.news · conservativedailynews.com · dailycallernewsfoundation.org · dnyuz.com · dreamnews.jp · dudensport.com · europesays.com · foreignpolicyjournal.com · fortbildung24.com · greekcitytimes.com · halifax.citynews.ca · independent.co.uk · independentmediacenter.org · information.tv5monde.com · kesq.com · keyt.com · kion546.com · knoxradio.com · kob.com · ksfr.org · kstp.com · lavozhispanact.com · liveblog.wtop.com · liveblogwp.wtop.com · localnews8.com · longevity.technology · mix929.com · nationalmemo.com · nclnet.org · newsable.asianetnews.com · newsmobile.in · nigerianewspapers.com.ng · notiulti.com · npr.org · nprinternedition.org · offthepress.com · omahadailyrecord.com · oslobodjenje.ba · pharmexec.com

This summary has been updated 1 time: see revision history